N-methyl-4-[4-[[4-[4-(methylcarbamoyl)phenoxy]phenyl]carbamoylamino]phenoxy]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-4-[4-[[4-[4-(methylcarbamoyl)phenoxy]phenyl]carbamoylamino]phenoxy]benzamide
• 化学式: C₂₉H₂₆N₄O₅
• 分子量: 510.549
• InChiKey: BLNKJKXISNHWFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Diaryl ureas with kinase inhibiting activity
  申请人：Wilhelm Scott

  公开号：US20070020704A1

  公开（公告）日：2007-01-25

  The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.

  本发明提供了使用芳基脲类化合物治疗与信号转导通路相关的疾病和病状的方法，该信号转导通路至少包括raf、VEGFR、PDGFR、p38和/或FLT-3。本发明还提供了用于鉴定可以通过本发明化合物调节的疾病和病状的组合物和方法。这些方法有助于选择可以有效治疗本发明化合物的受试者。此外，本发明还提供了监测已经接受本发明化合物治疗的受试者的方法。
• Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
  申请人：Riedl Bernd

  公开号：US20080032979A1

  公开（公告）日：2008-02-07

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于此类治疗的药物组合物。
• DIARYL UREAS AND COMBINATIONS
  申请人：Wilhelm Scott

  公开号：US20090068146A1

  公开（公告）日：2009-03-12

  The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I): B—NH—C(O)—NH-L-M-L 1 -(Q) 1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. each Q is independently C(O)R 4 , C(O)OR 4 and C(O)NR 4 R 5 ; and L′ is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.

  本发明提供了一种治疗人类和其他哺乳动物癌症的方法，包括给予化疗药物，如干扰素，和式（I）的芳基脲化合物：B—NH—C（O）—NH-L-M-L1-（Q）1-3（I）。在式（I）中，B和L各自独立地是可选取代的苯基，萘基，5或6个成员的单环杂芳基团，或8到10个成员的双环杂芳基团；M是桥接基；每个Q独立地是C（O）R4，C（O）OR4和C（O）NR4R5；L'是可选取代的苯基，萘基，单环杂芳基或双环杂芳基，或饱和或部分饱和的单环或双环碳环或杂环基团。
• Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
  申请人：Riedl Bernd

  公开号：US20080108672A1

  公开（公告）日：2008-05-08

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该治疗的制药组合物。
• omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors
  申请人：Riedl Bernd

  公开号：US20080027061A1

  公开（公告）日：2008-01-31

  This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗p38介导的疾病，以及用于该疗法的药物组合物。